EP3642400A1 - Methods and kits of constructing sequencing library for use in detecting chromosome copy number variation - Google Patents

Methods and kits of constructing sequencing library for use in detecting chromosome copy number variation

Info

Publication number
EP3642400A1
EP3642400A1 EP17914781.4A EP17914781A EP3642400A1 EP 3642400 A1 EP3642400 A1 EP 3642400A1 EP 17914781 A EP17914781 A EP 17914781A EP 3642400 A1 EP3642400 A1 EP 3642400A1
Authority
EP
European Patent Office
Prior art keywords
sequencing
dna
enzyme
double
adenine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP17914781.4A
Other languages
German (de)
French (fr)
Other versions
EP3642400B1 (en
EP3642400A4 (en
Inventor
Ling SHANG
Meng LV
Xiangbin CHEN
Tingting Wang
Jianguang Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Berry Genomics Co Ltd
Original Assignee
Berry Genomics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Berry Genomics Co Ltd filed Critical Berry Genomics Co Ltd
Publication of EP3642400A1 publication Critical patent/EP3642400A1/en
Publication of EP3642400A4 publication Critical patent/EP3642400A4/en
Application granted granted Critical
Publication of EP3642400B1 publication Critical patent/EP3642400B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B50/00Methods of creating libraries, e.g. combinatorial synthesis
    • C40B50/06Biochemical methods, e.g. using enzymes or whole viable microorganisms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1068Template (nucleic acid) mediated chemical library synthesis, e.g. chemical and enzymatical DNA-templated organic molecule synthesis, libraries prepared by non ribosomal polypeptide synthesis [NRPS], DNA/RNA-polymerase mediated polypeptide synthesis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Provided herein is a method of constructing a high throughput sequencing library for use in detecting chromosome copy number variation comprising mainly the following steps: (1) subjecting DNAs to be tested to random fragmentation by a double-strand DNA fragmentation enzyme; (2) end-filling and adding poly-adenine at the 3'end of the fragmented DNAs; (3) connecting the end-filled DNAs having a 3'end poly-adenine with sequencing linkers to obtain connected products; (4) purifying the connected products to obtain the sequencing library; wherein steps (1) - (3) are performed in a single reaction tube.Also provided is a kit for constructing a sequencing library for use in detecting chromosome copy number variation.

Description

    [Title established by the ISA under Rule 37.2] METHODS AND KITS OF CONSTRUCTING SEQUENCING LIBRARY FOR USE IN DETECTING CHROMOSOME COPY NUMBER VARIATION Technical field
  • The present invention relates to methods and kits of constructing a library. More particularly, the present invention relates to methods and kits of constructing a sequencing library for use in detecting abnormality in chromosome copy number.
  • Background
  • It has been reported that abnormality in chromosome number accounts for a great proportion of known abnormal chromosome-related diseases (Nagaoka et al., 2012) . Abnormality in chromosome number can be characterized not only by changes in number of whole chromosomes (such as chromosome aneuploidy) , but also by copy number variation (CNV) of certain fragments in certain chromosome (such as chromosome microdeletion microduplication syndrome) . As diseases caused by chromosome abnormality usually has high incidence, result in serious harm and lack effective treatment, it is important to detect accurately whether the copy number of chromosome is abnormal by technical means.
  • Currently, conventional karyotyping in combination with fluorescence in situ hybridization (FISH) or chromosome microarray analysis (CMA, such as aCGH and SNP-array) are main techniques and standards used in clinical for detecting chromosome copy number variation (Nord et al., 2015) . Karyotyping with high resolution, which was established in 1970s (Yunis, 1978; Trask, 2002) , is still the golden  standard in the detection of chromosome abnormality including chromosome aneuploidy, equilibrium or non-equilibrium structural rearrangement, deletion/duplication of large fragments, chimaera and the like. However, its resolution is relatively low (around 5Mb) , and is unable to detect copy number variation of small fragments of a chromosome with clinical significance. On the other hand, the FISH technique, which started in late 1980s, combines cytogenetics, immunology and molecular biology, and has well application in clinical study for detecting target chromosome aneuploidy and structure abnormality. However, the design of specific probe in this technique is limited by the information obtained from the target region, thus only limited information about the chromosome can be obtained. Recently developed chromosome microarray analysis (CMA) is a molecular karyotyping technique for high throughput detection of genomic DNA copy number variation, wherein relatively matured comparative genomic hybridization (aCGH) and single nucleotide polymorphism (SNP) array both are CMA techniques (Manning and Hudgins, 2010) . Although CMA has a high resolution compared with conventional karyotyping (Breman et al., 2012) , in clinical application, the microarray chip must be customized according to detailed chromosomal abnormalities and related clinical information in the public database. Thus, it is insufficient for the detection of certain microdelection and/or microduplication that is rare or not included in the database. In addition, the current CMA technology is difficult and has a high cost, thereby limiting its broad application in less developed areas. Thus, in order to investigating and diagnosing chromosomal diseases more widely, there is a need for an economical and simple method of detecting chromosome copy number variation accurately while ensuring the detection throughput and resolution.
  • In recent years, the increasingly mature next generation sequencing (NGS) technology has been widely used in clinical studies due to its prominent advantages like high throughput, high accuracy, high sensitivity, high automation and low operation cost (Xuan et al., 2013) . The most common principle employed in the detection of CNV by NGS is based on read-depth, i.e., determining the presence of CNV in certain fragments by calculating and comparing the depth of said fragments with the pre-calibrated theoretical value. This method applies to both single-end sequencing and paired-end sequencing (Yoon et al., 2009; Mason-Suares et al., 2016) . During the construction of a NGS library, a standard PCR is often used to amplify random fragments, while the amplification bias brought by the PCR method will inevitably affect the accuracy of the obtained data (van Dijk et al., 2014; Head et al., 2014; Goodwin et al., 2016) . Thus, it is critical to establish a simple PCR-free library construction method, thus to improve the detection accuracy of chromosome aneuploidy, in particular CNV.
  • Description of the Invention
  • The object of the present application is to provide a PCR-free method and kit of constructing a sequencing library for use in detecting variation in chromosome copy number, which overcomes the disadvantages of conventional methods for detecting the chromosome copy number variation in terms of resolution, coverage on the whole genome, throughput and cost, while addressing the problem of PCR amplification bias resulted in NGS library construction. Chromosome aneuploidy and chromosome microdeletion microduplication syndrome can be screened and diagnosed by using the method and kit of the present application to detect the chromosome copy number variation in a sample to be tested.
  • Thus, in a first aspect, the present application provides a method of constructing a sequencing library for use in detecting chromosome copy number variation, which mainly comprises the following steps:
  • (1) subjecting DNAs to be tested to random fragmentation by a double-strand DNA fragmentation enzyme;
  • (2) end-filling and adding poly-adenine tail at the 3’ end of the fragmented DNAs;
  • (3) connecting the end-filled DNAs having a 3’ end poly-adenine tail with linkers to obtain connected products;
  • (4) purifying the connected products to obtain the sequencing library;
  • wherein steps (1) - (3) are performed in a single reaction tube. Figure 1 shows the main steps of the method of the present application of constructing a sequencing library.
  • In one embodiment, the start amount of DNA to be tested preferably is 10-260ng. One skilled in the art knows that a suitable total amount of a library must not be less than 2fmol to meet the requirement of sequencing. Thus, to ensure the total amount of the constructed library to be at least equal to 2fmol, the inventors have found a preferable start amount of DNA to be tested of 10-260ng. If the amount is too low, the concentration of the obtained sequencing library will be not high enough to obtain effective sequencing data. On the other hand, if the amount is too high, the random fragmentation of DNAs to be tested will be inadequate. Thus, part of the DNAs to be tested still maintains its form of long fragment due to failure in fragmentation, and this part of DNAs cannot be effectively sequenced, which will have an impact on the concentration of the finally obtained library as well as the accuracy of its sequencing (see Example 2) .
  • In one embodiment, the double-strand DNA fragmentation enzyme  is an enzyme mixture of a nonspecific notch nuclease and a T7 endonuclease mutant. In particular, the nonspecific notch nuclease is a nuclease derived from Vibrio such as Vibrio vulnificus (Vvn) , wherein said nuclease is wild-type or a mutant thereof. The T7 endonuclease mutant is a T7 endonuclease having a mutation or mutations for example in the bridging region of two catalytic domains as disclosed in U.S. publication No. 2007-0042379. In one embodiment, the double-strand DNA fragmentation enzyme comprising a nonspecific notch nuclease and a T7 endonuclease mutant is known to one skilled in the art, for example, as those disclosed in the patent publication CN102301009A.
  • In one embodiment, the unit ratio between the nonspecific notch nuclease and the T7 endonuclease mutant is less than 1∶200, for example less than 1∶100 or less than 1∶10. The range thereof may be 1∶2-1∶200. Most preferably, the unit ratio between the nonspecific notch nuclease and the T7 endonuclease mutant is 1∶200. One unit of T7 endonuclease mutant is defined as the amount of enzyme required to convert 90%of 2 μg of the linear-nicked 2.44 kb dsDNA into two fragments (1.37 kb and 1.07 kb) at 37℃ for 1 hour. One unit of Vvn nuclease and mutants thereof is defined as the amount of enzyme required to release 1 A 260 unit of acid soluble oligonucleotides in 30 min at 37℃.
  • In one embodiment, the optimal incubation time for the DNA fragmentation reaction can be determined according to whether DNA has greater than 60%GC (high GC amount) , 40-60%GC (standard GC amount) or less than 40%GC (low GC amount) . For example, the incubation time typically may be in a range of 5-120min, for example 15-60min.
  • In one embodiment, the temperature of the DNA fragmentation reaction is 35-40℃, most preferably 37℃.
  • In one embodiment, the random fragmentation of DNA to be  detected is occurred in the presence of Buffer I, wherein said Buffer I mainly comprise 20mM trihydroxymethyl aminomethane-HCl (Tris-HCl) , 15mM magnesium chloride (MgCl 2) , 50mM sodium chloride (NaCl) , 0.1mg/ml bovine serum albumin (BSA) , and 0.15%Triton. The presence of Buffer I provide suitable reaction environment for the DNA fragmentation while maintaining the stability of the DNA fragmentation enzymes and improving the enzymatic activity thereof.
  • In one embodiment, there is a step of inactivating the double-strand DNA fragmentation enzymes between step (1) and step (2) . The inactivation of the double-strand DNA fragmentation enzymes is carried out in a water bath at 60-70℃, such as 65℃ for 10-13min, preferably in the presence of a buffer II, which comprises mainly 50mM NaCl, 10mM Tris-HCl, 10mM MgCl 2 and lmM dithiothreitol (DTT) . The presence of buffer II provides suitable ion concentrations for the inactivation of the enzyme, and also provides a suitable environment for the following reactions of end-filling and poly-adenine addition at 3’-end.
  • In one embodiment, any enzymes suitable for end-filling known by one skilled in the art can be used for end-filling of the present application. Examples of such enzymes include but not limited to T4 DNA polymerase, Klenow enzyme and the like. In one embodiment, any enzymes suitable for adding poly-adenine at 3’-end known by one skilled in the art can be used to add poly-adenine at 3’-end of the DNA. Examples of such enzymes include but not limited to the Taq enzyme, klenow ex-enzyme (an improved Klenow enzyme without 3’-5’ exonuclease activity, New England Biolabs) . In the method for constructing a library of the present invention, end-filling is carried out simultaneously with the poly-adenine addition, which simplifies the operation steps, saves the cost, while reducing possible contaminations  among samples.
  • In one embodiment, one skilled in the art can determine the incubation time and temperature used in the end-filing and poly-adenine addition at 3’-end as needed by conventional technologies.
  • In one embodiment, any enzymes suitable for connecting a sequencing linker known by one skilled in the art can be used. Examples of such enzymes include but not limited to T4 DNA ligase, T7 DNA ligase or their mixtures. The sequencing linkers used in the present invention are double-strand sequencing linkers matched to the sequencing platform, and can be selected by one skilled in the art according to conventional techniques. Preferably, the connecting step is carried out in the presence of buffer III, which mainly comprises 50mM NaCl, 10mM Tris-HCl, 10mM MgCl 2 and 0.1%bovine serum albumin (BSA) . The presence of buffer III provides a suitable environment for the connection reaction, and maintains the stability of the enzymes.
  • In one embodiment, a commercial kit of any reagents known by one skilled in the art can be used to purify the sequencing library obtained according to the construction method of the present application prior to sequencing. The obtained sequencing library is suitable for the second generation high-throughput sequencing platforms, such as HiSeq, MiSeq, MiniSeq, MySeq, NovaSeq sequencing platforms from Illumina, and PGM and Proton sequencing platforms from Thermo Fisher, and the like.
  • In a second aspect, the present invention provides a kit for constructing a sequencing library for use in detecting chromosome copy number variation, comprising: double-strand DNA fragmentation enzymes, buffer I, enzymes suitable for DNA end-filling, enzymes suitable for adding poly-adenine at 3’ end, sequencing linkers, ligase and buffer III, wherein the DNA fragmentation, DNA end-filling and  addition of poly-adenine at 3’ end are carried out in a single reaction tube. The kit may further comprise buffer II. The composition of buffer I, II and III are as described above.
  • In one embodiment, the kit according to the present invention further comprises a DNA sample used as a negative control, which is a normal DNA sample does not comprise chromosome copy number variation.
  • The method for constructing a library according to the present invention basically is completed by enzymatic reactions. The properties of easy inactivation of enzymes and different reacting temperatures in different steps make it possible to sequentially and continuously carrying out the three steps of DNA random fragmentation, end-filling and poly-adenine addition at 3’-end in a single reaction tube without DNA purification between the steps. As the construction method according to the present invention can be practiced in a single reaction tube, it also avoids sample loss and reduces sample contamination resulted from DNA sample transfer. Further, as only a small number of reagents are involved, the construction method and kit of the present application allow a relatively simple operation procedure, and is easy for practice. Moreover, the construction method according to the present application does not comprise a PCR step, thus avoiding amplification bias brought by the PCR operation per se, thereby improving the accuracy of the detection. Finally, the construction method and kit according to the present application can detect a sample DNA as less as 10ng accurately. That is, the initial amount of DNA sample required is low.
  • Figures
  • Figure 1 is a diagram illustrating the method for constructing a  library according to the present invention.
  • Figure 2 shows the sequencing results of a DNA sample to be tested (A) and a control normal sample (B) using libraries constructed according to the method of the present invention.
  • Figure 3 shows the sequencing results of a second DNA sample to be tested (A) and a control normal sample (B) using libraries constructed according to the method of the present invention.
  • Examples
  • Example 1: library construction according to the present invention and its use in DNA sequencing
  • This example detected the chromosome aneuploidy abnormality exemplified by Patau syndrome (T13) and chromosome microdeletion exemplified by chromosome 22q11.2 microdeletion syndrome, using the method and kit for constructing a a sequencing library for use in detecting chromosome copy number variation according to the present invention. Specifically, the Patau syndrome is a common trisomy syndrome, and is due to the presence of a third copy of chromosome 13. The chromosome 22q11.2 microdeletion syndrome is a clinical syndrome resulted from 22q11.21-q11.23 microdeletion in chromosome 22, and it is one of the most common microdeletion syndromes.
  • The sample DNAs are detected according to the following method.
  • 1. determining concentration: the concentration of DNA samples to be tested was measured by Qubit florometer, and the initial amounts of DNA samples were adjusted preferably as 10-260 ng.
  • 2. constructing a library: a sequencing library was constructed according to the method of the present application, which specifically comprises the following steps:
  • (1) preparing a reaction mixture on ice using DNA samples to be  tested and a negative control (a normal DNA sample) as indicated in Table 1.
  • Table 1:
  • Reagents Amount
    DNA sample 10ng
    Double-stranded DNA fragmentation enzyme 1μl
    Buffer I 1μl
    EB buffer add to 10μl
  • After thorough mixing, the reaction mixture is incubated at 37℃for 10 min.
  • (2) The reaction mixture was transferred onto ice, added with 7μl buffer II, and incubated for 10min at 65 ℃ after mixing thoroughly, so as to inactive the double-stranded DNA fragmentation enzyme. 
  • (3) The reaction mixture was transferred onto ice, added with 1.5μl T4 DNA polymerase and 1.5μl Taq enzyme, and then added to 50μl using the EB buffer. After thorough mixing, the reaction mixture was centrifuged for 5s at room temperature instantly, and bubbles were removed by slight flicks. Then, the reaction mixture was placed in a normal PCR machine (or a thermo metal bath) to carry out the following incubation steps: 20min at 37 ℃, followed by 20 min at 72 ℃, and finally 5 min at 4℃.
  • (4) After incubation in the PCR machine (or a thermo metal bath) , the reaction mixture was took out and placed on ice. Meanwhile, a pre-mixture is prepared according to Table 2.
  • Table 2:
  • Reagents Amount
    Buffer III 25μl
    T4 DNA ligase 1μl
  • The pre-mixture was mixed thoroughly and centrifuged for 5s at  room temperature instantly. Then, the pre-mixture was added to the incubated reaction mixture, and 2μl of sequencing linkers was added on the wall of the same reaction tube, followed by centrifugation for 5s at room temperature instantly. After rapid mixing, the mixture was centrifuged for 5s at room temperature instantly, and bubbles were removed by slight flicks. The mixture was centrifuged for 5s at room temperature instantly again. Then, the reaction mixture was placed in a normal PCR machine (or a thermo metal bath) to carry out the following incubation steps: 15min at 20℃, followed by 10 min at 65℃, and finally 5 min at 4 ℃. The sequencing library was obtained after the incubation.
  • 3. purifying the library and sequencing: the obtained sequencing library was purified using a purification kit from Hangzhou Berry Genomics Diagnostic Technology Ltd. (Lot No.: R0022) , and the total amount is not less than 2fmol. Then, the purified sequencing library was loaded and sequenced on a NextSeq CN500 sequencing machine (National Medical Instrument Registration No.: 20153400460) according to the instructions of the manufactures.
  • 4. analyzing the sequencing results: the sequencing results were aligned with the human genome reference sequences. The detection results of chromosome copy number in samples to be tested and in normal samples are presented in Figures 2 and 3.
  • In Figures 2 and 3, “ration” indicated in the Y-axis log 2 (ratio) refers to the ratio between the copy number of the detected region and 2 (i.e., diploid) , and the X-axis represents the whole chromosome region. The whole chromosome region was evenly divided into lots of bins, wherein the log 2 (ratio) value of each bin corresponds to a single dot, and the distribution of all dots was used to obtain a trend line (the grey line) . The black line in Figures 2 and 3 represents location of centromere in the chromosome, and separates the chromosome into a short arm and a  long arm. As there are no reference sequences for the short arms of chromosomes 13 and 22 in the current human genome reference sequences that can be used for data analysis, the sequencing results related to the short arms of chromosomes 13 and 22 cannot be analyzed, resulting in the absence of corresponding log 2 (ratio) values in these regions.
  • Specifically, Figure 2 shows the detection results of copy number in the chromosome 13 region of a DNA sample to be tested (A) and a normal sample (B) . It is clear that for the DNA sample to be tested, the log 2 (ratio) value of the long arm of chromosome 13 is around 0.585 (=log 21.5) , indicating that at least there are three copies for long arm part of the chromosome 13. That is, the DNA sample to be tested has Patau Sydrome (T13) . Meanwhile, for the normal sample, the log 2 (ratio) value of the long arm of chromosome 13 is 0 (=log 21) , indicating that the chromosome 13 has only two copies. The DNA sample to be tested was detected by SNP-array, which confirmed the presence of three copies of chromosome 13 long arm. In other words, the detection results obtained using the library construction method and kit of the present invention are consistent with the clinical detection results.
  • The inventors also used the method and kit of the present invention to construct second libraries for a second DNA sample to be tested and a normal sample and then performed sequencing as indicated above. The results are shown in Figure 3. It is clear that for this DNA sample to be tested, the log 2 (ratio) value of chromosome 22 in the 20M region is around -1 (=log 20.5) , indicating that this region has only one copy. When aligned to the human genome reference sequences, this region with only one copy corresponds to the 22q11.21-q11.23 region. Thus, the DNA sample to be tested was confirmed to have a chromosome 22q11.2 microdeletion syndrome. Meanwhile, for the normal sample, the  log 2 (ratio) value of the long arm of chromosome 22 is 0 (=log 21) , indicating that there is no deletion in 22q11.2 region of chromosome 22. The DNA sample to be tested was detected by SNP-array, which confirmed the presence of microdeletion in 22q11.2 region of chromosome 22. In other words, the detection results obtained using the library construction method and kit of the present invention are consistent with the clinical detection results.
  • This example shows that the library construction method and kit of the present invention can be used for constructing a sequencing library which allows the accurate detection of chromosome copy number variation by high throughput sequencing.
  • Example 2: The effects of initial amount of DNA on the concentration of sequencing library
  • Samples with various initial amounts of DNA were used to prepare sequencing libraries according to the library construction and purification method of Example 1, and the total amount of obtained libraries were measured. The results are represented in Table 3.
  • Table 3: The DNA initial amounts and the total amounts of finally obtained libraries
  • Table 3 shows that when the DNA initial amount is between 10 and 260ng, the total amounts of the obtained libraries generally are greater than 2 fmol, which satisfies the requirements for sequencing. However, when the DNA initial amount is too low or too high, the total amounts of the obtained libraries are less than 2fmol, which is not optimal for sequencing. Thus, in the present invention, the DNA initial amount ufsed for preparing a sequencing library preferably is 10-260n1.812g.
  • It should be note that the above examples are merely the preferred embodiments of the invention and are not intended to limit the invention. Those skilled in the art know there can be various modifications and changes. Those skilled in the art will understand that any modification, equivalent replacement and improvement within the spirit and principle of the invention will be encompassed in the protection scope of the invention.
  • References
  • Nagaoka SI, Hassold TJ, and Hunt PA. Human aneuploidy: mechanisms and new insights into an age-old problem. Nat. Rev. Genet. 2012, 13: 493e504
  • Nord A, Salipante SJ, Pritchard C. Chapter 11-Copy Number Variant Detection Using Next-Generation Sequencing. Clinical Genomics, 2015, 8: 165-187
  • Yunis J. High-resolution chromosome analysis in clinical medicine.  Prog. Clin. Pathol., 1978, 7: 267-288
  • Trask BJ. Human cytogenetics: 46 chromosomes, 46 years and counting. Nat. Rev. Genet. 2002, 3: 769e778
  • Trask BJ. Fluoresence in situ hybridization: application in cytogenetics and gene mapping. Trends Gnent. 1991, 7: 149-154.
  • Manning M, and Hudgins L. Array-based technology and recommendations for utilization in medical genetics practice for detection of chromosomal abnormalities. Genet. Med. 2010, 12 (11) : 742-745.
  • Breman A, Pursley AN, Hixson P, Bi W, Ward P, Bacino CA, Shaw C, Lupski JR, Beaudet A, Patel A, Cheung SW, Van den Veyver I: Prenatal chromosomal microarray analysis in a diagnostic laboratory: experience with >1000 cases and review of the literature. Prenat. Diagn. 2012, 32: 351e361.
  • Xuan J, Yu Y, Qing T, Guo L, Shi L. Next-generation sequencing in the clinic: promises and challenges. Cancer Lett. 2013, 340 (2) : 284-295.
  • Yoon S, Xuan Z, Makarov V, Ye K, Sebat J. Sensitive and accurate detection of copy number variants using read depth of coverage. Genome Res. 2009, 19 (9) : 1586-1592.
  • Mason-Suares H, Landry L, Lebo MS. Detecting Copy Number Variation via Next Generation Technology. Curr. Genet. Med. Report. 2016, 4 (3) : 1-12.
  • van Dijk EL, Jaszczyszyn Y, Thermes C. Library preparation methods for next-generation sequencing: tone down the bias. Exp. Cell Res. 2014, 322 (1) : 12-20.
  • Head SR, Komori HK, LaMere SA, Whisenant T, Van Nieuwerburgh F, Salomon DR, Ordoukhanian P1. Library construction for next-generation sequencing: overviews and challenges.  Biotechniques. 2014, 56 (2) : 61-64.
  • Goodwin S, McPherson JD, McCombie WR. Coming of age: ten years of next-generation sequencing technologies. Nat. Rev. Genet. 2016, 17 (6) : 333-351.

Claims (17)

  1. A method of rapidly constructing a high throughput sequencing library for use in detecting chromosome copy number variation, characterized in that, the method comprises the following steps:
    (1) subjecting DNAs to be tested to random fragmentation by a double-strand DNA fragmentation enzyme;
    (2) end-filling and adding poly-adenine at the 3’ end of the fragmented DNAs;
    (3) connecting the end-filled DNAs having a 3’ end poly-adenine with sequencing linkers to obtain connected products;
    (4) purifying the connected products to obtain the sequencing library;
    wherein steps (1) - (3) are performed in a single reaction tube.
  2. The method according to claim 1, characterized in that, there is no DNA purification steps among steps (1) - (3) .
  3. The method according to claim 1, characterized in that, the method does not comprise a step of PCR amplification.
  4. The method according to claim 1, characterized in that, there is a step of inactivating the double-strand DNA fragmentation enzymes between the step (1) and step (2) .
  5. The method according to claim 1, characterized in that, the double-strand DNA fragmentation enzyme is an enzyme mixture of a nonspecific notch nuclease and a T7 endonuclease mutant.
  6. The method according to claim 4, characterized in that, the nonspecific notch nuclease is a Vvn nuclease, and the T7 endonuclease mutant is a T7 endonuclease having a mutation or mutations in the bridging region of two catalytic domains.
  7. The method according to claim 1, characterized in that, step (2) is carried out by T4 DNA polymerase and Taq enzyme.
  8. The method according to claim 1, characterized in that, the sequencing linkers are double-strand sequencing linkers matched to sequencing platforms.
  9. The method according to claim 1, characterized in that, step (3) is carried out by T4 DNA ligase.
  10. The method according to claim 1, characterized in that, the sequencing library is suitable for the second generation high throughput sequencing platforms.
  11. A kit for constructing a sequencing library for use in detecting chromosome copy number variation, characterized in that, the kit comprises: double-strand DNA fragmentation enzymes and buffer I for DNA fragmentation, enzymes for DNA end-filling, enzymes for adding poly-adenine at 3’ end, sequencing linkers, ligase and buffer III for ligation, wherein the DNA fragmentation, DNA end-filling and addition of poly-adenine at 3’ end are carried out in a single reaction tube.
  12. The kit according to claim 11, characterized in that, the double-strand DNA fragmentation enzyme is an enzyme mixture of a nonspecific notch nuclease and a T7 endonuclease mutant.
  13. The kit according to claim 12, characterized in that, the nonspecific notch nuclease is a Vvn nuclease, and the T7 endonuclease mutant is a T7 endonuclease having a mutation or mutations in the bridging region of two catalytic domains.
  14. The kit according to claim 11, characterized in that, the enzyme for DNA end-filling is T4 DNA polymerase, and the enzyme for adding poly-adenine at 3’ end is Taq enzyme.
  15. The kit according to claim 11, characterized in that, the sequencing linkers are double-strand sequencing linkers matched to sequencing platforms.
  16. The kit according to claim 11, characterized in that, the ligase is  T4 DNA ligase.
  17. The kit according to claim 11, characterized in that, it further comprises buffer II for inactivating the double-strand DNA fragmentation enzymes.
EP17914781.4A 2017-06-21 2017-12-11 Methods and kits of constructing sequencing library for use in detecting chromosome copy number variation Active EP3642400B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710476884.1A CN107217308A (en) 2017-06-21 2017-06-21 A kind of sequencing library construction method and kit for being used to detect chromosome copies number variation
PCT/CN2017/115378 WO2018233236A1 (en) 2017-06-21 2017-12-11 Methods and kits of constructing sequencing library for use in detecting chromosome copy number variation

Publications (3)

Publication Number Publication Date
EP3642400A1 true EP3642400A1 (en) 2020-04-29
EP3642400A4 EP3642400A4 (en) 2020-12-16
EP3642400B1 EP3642400B1 (en) 2022-12-07

Family

ID=59949927

Family Applications (1)

Application Number Title Priority Date Filing Date
EP17914781.4A Active EP3642400B1 (en) 2017-06-21 2017-12-11 Methods and kits of constructing sequencing library for use in detecting chromosome copy number variation

Country Status (5)

Country Link
US (1) US20200131507A1 (en)
EP (1) EP3642400B1 (en)
JP (1) JP2020529219A (en)
CN (1) CN107217308A (en)
WO (1) WO2018233236A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107217308A (en) * 2017-06-21 2017-09-29 北京贝瑞和康生物技术股份有限公司 A kind of sequencing library construction method and kit for being used to detect chromosome copies number variation
CN111379032A (en) * 2018-12-28 2020-07-07 北京贝瑞和康生物技术有限公司 Method and kit for constructing sequencing library for simultaneously realizing genome copy number variation detection and gene mutation detection
CN109797436B (en) * 2018-12-29 2021-10-08 阅尔基因技术(苏州)有限公司 Sequencing library construction method
CN116144735A (en) * 2019-08-12 2023-05-23 深圳市真迈生物科技有限公司 Nucleic acid sample processing method, sequencing method and kit
CN111020018B (en) * 2019-11-28 2021-09-14 天津金匙医学科技有限公司 Macrogenomics-based pathogenic microorganism detection method and kit
CN111763664B (en) * 2020-06-28 2021-03-26 江苏康科斯医疗科技有限公司 Enzyme reaction liquid for constructing sequencing library and application thereof
CN113667715A (en) * 2021-08-11 2021-11-19 广州达安基因股份有限公司 Construction method and kit for detecting pathogen DNA library in respiratory tract sample
CN113512766A (en) * 2021-08-25 2021-10-19 广州达安基因股份有限公司 Construction method of DNA next generation sequencing library
CN114197061A (en) * 2022-02-17 2022-03-18 北京贝瑞和康生物技术有限公司 Method and kit for constructing sequencing library for detecting chromosome copy number variation
CN114457143A (en) * 2022-03-16 2022-05-10 苏州贝康医疗器械有限公司 Method for constructing CNV detection library and CNV detection method

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005052124A2 (en) * 2003-11-21 2005-06-09 New England Biolabs, Inc. Modified dna cleaving enzymes and methods of use
CN102301009B (en) * 2009-02-03 2015-09-30 新英格兰生物实验室公司 Enzyme is used to produce random ds breakage in DNA
JP5780971B2 (en) * 2009-03-09 2015-09-16 ニユー・イングランド・バイオレイブス・インコーポレイテツド Random double-strand breaks in DNA using enzymes
US20130203606A1 (en) * 2010-02-25 2013-08-08 Advanced Liquid Logic Inc Method of Preparing a Nucleic Acid Library
WO2012024658A2 (en) 2010-08-20 2012-02-23 IntegenX, Inc. Integrated analysis system
CN102108406B (en) * 2010-12-20 2014-05-21 北京贝瑞和康生物技术有限公司 Kit, device and method for detecting copy number of embryo chromosomes
CN103080336B (en) * 2011-05-31 2014-06-04 北京贝瑞和康生物技术有限公司 Kits, devices and methods for detecting chromosome copy number of embryo or tumor
CN103987856B (en) * 2011-12-17 2016-08-24 深圳华大基因股份有限公司 Determine whether genome exists abnormal method and system
WO2013104106A1 (en) * 2012-01-10 2013-07-18 北京贝瑞和康生物技术有限公司 Method for construction of plasma dna sequencing library and kit thereof
HUE058149T2 (en) * 2014-01-31 2022-07-28 Swift Biosciences Inc Improved methods for processing dna substrates
CN111748606A (en) * 2014-06-24 2020-10-09 北京贝瑞和康医学检验实验室有限公司 Method and kit for quickly constructing plasma DNA sequencing library
CN104694654B (en) * 2015-03-18 2018-04-13 北京明谛生物医药科技有限公司 A kind of kit for detecting fetal chromosomal Number Variation
CN105734048A (en) * 2016-02-26 2016-07-06 武汉冰港生物科技有限公司 PCR-free sequencing library preparation method for genome DNA
CN106148513A (en) * 2016-06-22 2016-11-23 杭州杰毅麦特医疗器械有限公司 A kind of dissociative DNA library constructing method and test kit
CN106497920A (en) * 2016-11-21 2017-03-15 深圳华大基因研究院 A kind of library constructing method and test kit for nonsmall-cell lung cancer detection in Gene Mutation
CN106755337A (en) * 2016-11-30 2017-05-31 杭州杰毅麦特医疗器械有限公司 A kind of cell chromosome analyzes quick banking process and kit
CN107217308A (en) * 2017-06-21 2017-09-29 北京贝瑞和康生物技术股份有限公司 A kind of sequencing library construction method and kit for being used to detect chromosome copies number variation

Also Published As

Publication number Publication date
US20200131507A1 (en) 2020-04-30
EP3642400B1 (en) 2022-12-07
WO2018233236A1 (en) 2018-12-27
JP2020529219A (en) 2020-10-08
CN107217308A (en) 2017-09-29
EP3642400A4 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
EP3642400B1 (en) Methods and kits of constructing sequencing library for use in detecting chromosome copy number variation
US20200385810A1 (en) Methods for determining fraction of fetal nucleic acids in maternal samples
EP3382037B1 (en) Methods for determining fraction of fetal nucleic acids in maternal samples
US20120003657A1 (en) Targeted sequencing library preparation by genomic dna circularization
US20050037388A1 (en) Method for detecting diseases caused by chromosomal imbalances
KR20070031923A (en) Detection of chromosomal disorders
US20020132259A1 (en) Mutation detection using MutS and RecA
WO2017123316A1 (en) Deep sequencing profiling of tumors
US20170327868A1 (en) Blocker based enrichment system and uses thereof
US20110091900A1 (en) Method for determining dna copy number by competitive pcr
JP2021513858A (en) Improved detection of microsatellite instability
AU2016325100A1 (en) Probe set for analyzing a DNA sample and method for using the same
US20200277651A1 (en) Nucleic Acid Preparation and Analysis
US8206905B2 (en) Enzymatic time-resolved luminescent assay for nucleic acids quantitation
EP2464754B1 (en) Amelogenin snp on chromosome x
US20230002814A1 (en) Array-based methods for analysing mixed samples using differently labelled allele-specific probes
US20220364173A1 (en) Methods and systems for detection of nucleic acid modifications
US20230183789A1 (en) A method of detecting structural rearrangements in a genome
CN110914448A (en) Array-based method for analyzing mixed samples using differentially labeled allele-specific probes
Moldovan et al. Multiplex ligation-dependent probe amplification–a short overview
Gallardo et al. Application to Assisted Reproductive of Whole-Genome Treatment Technologies
US20080090235A1 (en) Unstructured nucleic acid PCR primers and methods of using the same
CA3195721A1 (en) Compositions and methods for isolation of cell-free dna
Gallardo et al. Application of Whole-Genome Technologies to Assisted Reproductive Treatment
WO2004046688A2 (en) Cftr allele detection assays

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200120

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20201116

RIC1 Information provided on ipc code assigned before grant

Ipc: C40B 50/06 20060101AFI20201110BHEP

Ipc: C12Q 1/68 20180101ALI20201110BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20211025

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BERRY GENOMICS CO., LTD

INTG Intention to grant announced

Effective date: 20220721

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1536345

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221215

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017064509

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG9D

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20221207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230307

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1536345

Country of ref document: AT

Kind code of ref document: T

Effective date: 20221207

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230308

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230601

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230410

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20221231

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221211

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20230407

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602017064509

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221211

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231

26N No opposition filed

Effective date: 20230908

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20221231

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231221

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20231221

Year of fee payment: 7

Ref country code: DE

Payment date: 20231219

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20171211

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20221207